A Randomized, Single-Blind, Placebo-Controlled, Single-Center, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Fasting After Single Ascending Oral Doses of AZD5658 in Type 2 Diabetes Mellitus Patients.
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2012
At a glance
- Drugs AZD 5658 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 01 Feb 2012 Actual patient number is 24 according to ClinicalTrials.gov.
- 22 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2010 Planned End Date changed from 1 Oct 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.